PROF
Profound Medical Corp.NASDAQHealthcareAs of 2026-04-06
Valuation
View DetailsP/E (TTM)
—
PEG
—
P/B
2.15
P/S
10.47
EV/EBITDA
-2.76
DCF Value
$-22.04
FCF Yield
-21.2%
Div Yield
0.0%
Margins & Returns
Gross Margin
70.2%
Operating Margin
-239.5%
Net Margin
-248.5%
ROE
-85.7%
ROA
-23.7%
ROIC
-23.8%
Financials
View All| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q4 2025 | $6.1M | $-8.3M | $-0.27 |
| FY 2025 | $16.1M | $42.3M | $1.41 |
| Q3 2025 | $5.2M | $-7.9M | $-0.37 |
| Q2 2025 | $2.2M | $-15.7M | $-0.52 |
Analyst Ratings
View AllTrading Activity
Insider Trades
View AllCompany Info
Sector
Healthcare
Industry
—
Country
CA
Exchange
NASDAQ
Beta
0.47
Profound Medical Corp., together with its subsidiaries, operates as a commercial-stage medical device company that develops magnetic resonance guided ablation procedures for treatment of prostate disease, uterine fibroids, and palliative pain treatment in Canada, Germany, the United States, and Finland. Its lead product TULSA-PRO system used for magnetic resonance imaging scanner in hospitals and treatment facilities. The company also offers Sonalleve, a therapeutic platform for the treatment of uterine fibroids and palliative pain relief associated with metastases in bone, as well as non-invasive treatment of uterine fibroids. Profound Medical Corp. is headquartered in Mississauga, Canada.